Your session is about to expire
← Back to Search
18F-DCFPyL Imaging for Prostate Cancer
Study Summary
This trial is testing an imaging agent to see if it can help detect response to prostate cancer treatment.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2019 Phase 3 trial • 208 Patients • NCT03739684Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- My cancer has spread beyond the prostate.My hepatitis C is cured or currently treated with no detectable virus.I have prostate cancer confirmed by MRI and biopsy.I cannot undergo radiation or SBRT due to health reasons.My hepatitis B virus load is undetectable with treatment.I am 18 years old or older.I have had hormone therapy, radiation, or surgery for prostate cancer.I have prostate cancer confirmed by biopsy and plan to undergo SBRT with or without hormone therapy.I agree to use effective birth control or abstain from sex during the study and for 2 months after the last scan.I am able to care for myself and perform daily activities.I have HIV but am on effective treatment with an undetectable viral load in the last 6 months.I am scheduled for radiation therapy targeting the lymph nodes in my pelvis.
- Group 1: 18F-DCFPyL imaging
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
What applications is 18F-DCFPyL mainly employed for?
"18F-DCFPyL is commonly prescribed to patients with abnormally high serum prostate specific antigen (PSA) readings. This medication may also be beneficial for those suspected of having metastasis, undergoing positron emission tomography, or managing recurrent prostate cancer."
Has 18F-DCFPyL been sanctioned by the FDA for use?
"18F-DCFPyL has been assigned a safety rating of 2, as it is currently undergoing Phase 2 trials. Although some preliminary information regarding its safety can be found, there are no reports on efficacy yet."
How many participants are receiving treatment in this medical study?
"Indeed, the information on clinicaltrials.gov signposts that this trial is actively recruiting participants. It was initially posted on August 31st 2022 and has been recently updated October 15th 2022. This medical research requires 120 patients to be enrolled at a single location."
Are there any openings for volunteers to participate in this trial?
"Affirmative. According to the clinicaltrials.gov records, this research is actively seeking participants after having been posted on August 31st 2022 and recently updated on October 15th 2022. The study requires 120 subjects from a single site for recruitment purposes."
What empirical studies has 18F-DCFPyL been the focus of?
"At this time, 18F-DCFPyL is the subject of eighteen distinct clinical trials. None are in Phase 3 yet. Most studies for this medication take place in Baltimore, Maryland but there are 27 other locations where research is ongoing."
Share this study with friends
Copy Link
Messenger